Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.17 -7.9%	$5.36	$1.67 ▼ $7.29	$512.98M	0.94	2.40 million shs	3.39 million shs
PRTC PureTech Health	$17.72 +3.3%	$18.27	$13.30 ▼ $25.00	$427.56M	1.12	4,373 shs	5,874 shs
SKYE Skye Bioscience	$3.29 -6.2%	$3.46	$1.14 ▼ $7.47	$101.96M	2.21	680,523 shs	282,356 shs
SVRA Savara	$2.79 +3.1%	$2.36	$1.89 ▼ $4.70	$481.36M	0.4	1.20 million shs	238,847 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+5.85%	+11.75%	+5.85%	+69.49%	+208.24%
PRTC PureTech Health	-0.58%	-9.16%	-2.56%	+0.88%	-19.67%
SKYE Skye Bioscience	-0.28%	-3.31%	-11.81%	+80.93%	-22.35%
SVRA Savara	+2.27%	+5.06%	+12.97%	-9.09%	-32.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.0609 of 5 stars	3.6	1.0	2.1	1.7	0.6
PRTC PureTech Health	1.7861 of 5 stars	3.8	3.0	0.0	0.0	0.0
SKYE Skye Bioscience	1.2393 of 5 stars	3.5	2.0	1.0	0.0	0.0
SVRA Savara	1.8059 of 5 stars	3.3	0.0	1.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	260.07% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	162.39% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	372.93% Upside
SVRA Savara	2.60	Moderate Buy	$5.60	107.41% Upside

Current Analyst Ratings Breakdown

Latest SKYE, SVRA, ATYR, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,390.10	N/A	N/A	$0.83 per share	6.76
PRTC PureTech Health	$4.83M	85.68	$2.37 per share	7.24	$17.04 per share	1.01
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	8/12/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-69.28%	-64.25%	N/A
SVRA Savara	-$95.88M	-$0.48	N/A	N/A	N/A	N/A	-65.88%	-52.35%	N/A

Latest SKYE, SVRA, ATYR, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
PRTC PureTech Health	N/A	9.33	9.33
SKYE Skye Bioscience	N/A	11.85	11.85
SVRA Savara	0.20	14.91	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
PRTC PureTech Health	0.04%
SKYE Skye Bioscience	21.09%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
PRTC PureTech Health	5.30%
SKYE Skye Bioscience	3.00%
SVRA Savara	5.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable
SKYE Skye Bioscience	11	30.99 million	30.06 million	Optionable
SVRA Savara	20	172.84 million	163.97 million	Optionable

SKYE, SVRA, ATYR, and PRTC Headlines

Recent News About These Companies

Savara (SVRA) to Release Earnings on Monday

August 9 at 2:41 AM | americanbankingnews.com

Savara (SVRA) Projected to Post Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Invests $381,000 in Savara Inc. (NASDAQ:SVRA)

August 4, 2025 | marketbeat.com

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating

August 1, 2025 | msn.com

Savara: Repairing The Molbreevi aPAP Opportunity After RTF

July 22, 2025 | seekingalpha.com

Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

July 20, 2025 | marketbeat.com

Savara Announces New Employment Inducement Grant

July 18, 2025 | businesswire.com

Emerald Advisers LLC Raises Position in Savara Inc. (NASDAQ:SVRA)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Purchases 638,568 Shares of Savara Inc. (NASDAQ:SVRA)

July 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 6, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 27, 2025 | prnewswire.com

Savara Independent Director Acquires 177% More Stock

June 25, 2025 | finance.yahoo.com

Richard J. Hawkins Purchases 48,225 Shares of Savara Inc. (NASDAQ:SVRA) Stock

June 24, 2025 | insidertrades.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 16, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 13, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 12, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 11, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, SVRA, ATYR, and PRTC Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.16 -0.45 (-7.93%)

As of 02:31 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

PureTech Health NASDAQ:PRTC

$17.72 +0.57 (+3.32%)

As of 12:19 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Skye Bioscience NASDAQ:SKYE

$3.29 -0.22 (-6.18%)

As of 02:31 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Savara NASDAQ:SVRA

$2.78 +0.09 (+3.15%)

As of 02:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time